Evidence mapPaperPMID 42370171Full record

ArticleTheranostics2026

Targeted RNA Therapy Reprograms Fibrotic Macrophages to Reverse Pulmonary Fibrosis.

Zhimin Song, Jingjing Chen, Jiaying Fan, Tinghong Zhang, Xing Peng, Yao Pan, Yun Zhang, Yaofeng Wang, Jinling Qin, Shu Meng

Abstract read
In one paragraph

Article in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zhimin SongState Key Laboratory of Respiratory Disease, the First Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 510120, China.
Jingjing ChenState Key Laboratory of Respiratory Disease, the First Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 510120, China.
Jiaying FanState Key Laboratory of Respiratory Disease, the First Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 510120, China.
Tinghong ZhangState Key Laboratory of Respiratory Disease, the First Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 510120, China.
Xing PengState Key Laboratory of Respiratory Disease, the First Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 510120, China.
Yao PanState Key Laboratory of Respiratory Disease, the First Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 510120, China.
Yun ZhangDepartment of Basic Science Research, Guangzhou National Laboratory, Guangzhou, Guangdong, 510005, China.
Yaofeng WangDepartment of Basic Science Research, Guangzhou National Laboratory, Guangzhou, Guangdong, 510005, China.
Jinling QinDepartment of Basic Science Research, Guangzhou National Laboratory, Guangzhou, Guangdong, 510005, China.
Shu MengState Key Laboratory of Respiratory Disease, the First Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 510120, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rationale: Pulmonary fibrosis is driven by maladaptive immune programs that reinforce fibroblast activation. We sought to determine whether profibrotic macrophage states could be therapeutically remodeled to alleviate fibrosis through targeted RNA-based modulation of their intrinsic regulatory circuitry. Methods: Integrated single-cell transcriptomic and metabolomic analyses were performed to identify regulatory programs associated with profibrotic macrophage states during lung fibrosis. A mannose-functionalized lipid nanoparticle platform was developed to preferentially deliver regulatory RNAs to CD206⁺ macrophages Results: Transcriptomic and metabolomic analyses identified an Arg1-centered metabolic module that stabilizes profibrotic macrophage states during lung fibrosis. The mannose-functionalized lipid nanoparticle system enabled preferential RNA delivery to CD206⁺ macrophages Conclusions: These findings demonstrate that macrophage states can be therapeutically remodeled through targeted RNA-based modulation in pulmonary fibrosis. This strategy establishes state-level immune reprogramming as a potentially generalizable approach for dismantling pathogenic immune programs in fibrotic disease.

Indexed as

MacrophagesPulmonary FibrosisAnimalsArginaseGene Expression ProfilingInterferon Regulatory FactorsLectins, C-TypeMannose-Binding LectinsMannose ReceptorMiceMice, Inbred C57BLNanoparticlesRNA, MessengerArg1 protein, mouseArginaseInterferon Regulatory FactorsIrf5 protein, mouseLectins, C-TypeMannose-Binding LectinsMannose ReceptorRNA, Messengerarginase-1immunometabolismmacrophage reprogrammingpulmonary fibrosisRNA therapeutics

Identifiers

PMID42370171
PMCPMC13294990

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.